Charles Schwab Investment Management Inc Kaleido Biosciences, Inc. Transaction History

Charles Schwab Investment Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.05 - $1.7 $2,054 - $69,842	-41,084 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.3 - $2.7 $11,063 - $22,977	-8,510 Reduced 17.16%	41,084 $68,000
Q3 2021 Nov 16, 2021	SELL	$5.36 - $7.99 $487,138 - $726,163	-90,884 Reduced 64.7%	49,594 $271,000
Q2 2021 Aug 16, 2021	BUY	$5.82 - $8.72 $84,774 - $127,015	14,566 Added 11.57%	140,478 $1.05 Million
Q1 2021 May 17, 2021	BUY	$7.2 - $16.82 $254,505 - $594,553	35,348 Added 39.03%	125,912 $1.02 Million
Q4 2020 Feb 16, 2021	SELL	$5.77 - $11.33 $27,984 - $54,950	-4,850 Reduced 5.08%	90,564 $825,000
Q3 2020 Nov 13, 2020	BUY	$5.09 - $11.07 $280,428 - $609,890	55,094 Added 136.64%	95,414 $1.06 Million
Q2 2020 Aug 14, 2020	SELL	$4.62 - $8.01 $4,144 - $7,184	-897 Reduced 2.18%	40,320 $300,000
Q1 2020 May 15, 2020	BUY	$3.62 - $9.49 $1,455 - $3,814	402 Added 0.98%	41,217 $254,000
Q4 2019 Feb 07, 2020	BUY	$5.02 - $8.87 $64,235 - $113,500	12,796 Added 45.67%	40,815 $205,000
Q3 2019 Nov 08, 2019	SELL	$6.74 - $11.3 $15,973 - $26,781	-2,370 Reduced 7.8%	28,019 $211,000
Q2 2019 Aug 09, 2019	BUY	$11.25 - $18.1 $341,876 - $550,040	30,389 New	30,389 $353,000

2.65K

Ticker KLDO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,622,600
Description
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the tr...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.